| Similar Articles |
|---|
 |
The Motley Fool
October 31, 2006
Brian Gorman |
Kendle's New Risk The drug development services company continues to deliver, but new debt poses some risk to future earnings. In the near term, investors could be in for a bumpy ride.   |
The Motley Fool
November 1, 2005
Brian Gorman |
Kendle's Resurgence Can the contract pharmaceutical researcher continue its growth without more acquisitions? Despite the vibrant growth and its operational progress, Kendle still is at a disadvantage to larger rivals like Charles River Laboratories and PPD. |
The Motley Fool
February 15, 2005
Brian Gorman |
Kendle Grows With Client Base The contract drug research company shares surged as the firm showed signs of new life. |
The Motley Fool
February 14, 2006
Brian Gorman |
Kendle's on Solid Ground The contract research services outfit is on track for another good year. Investors, take note. |
The Motley Fool
April 20, 2011
Brandon Glenn |
Growing CRO Demand Boosts Outlook for Kendle It's been rough going lately for Kendle. |
The Motley Fool
January 25, 2006
Brian Gorman |
PAREXEL Recovers The clinical research services company is in better shape, but it still has progress to make. Investors should approach the company with some caution. |
Bio-IT World
April 2007
Deborah Borfitz |
EDC Guru Moves from Novartis to Kendle The publicly owned clinical research organization Kendle recently brought the pragmatic Sylva Collins on board to provide leadership for its global biometrics offerings and help it become "the unparalleled leader in e-clinical services." |
